Loading...
Loading...
Medical Disclaimer: This information is for educational purposes only and is not a substitute for professional medical advice.
Brand Name
Vilazodone
Generic Name
Vilazodone Hydrochloride
Active Ingredient
VilazodoneCategory
Other
Salt Form
Hydrochloride
Variants
6
Different strengths and dosage forms
| Strength | Form | Route | NDC |
|---|---|---|---|
| 10 mg/1 | TABLET | ORAL | 42291-948 |
| 20 mg/1 | TABLET | ORAL | 60505-4773 |
| 40 mg/1 | TABLET | ORAL | 42291-950 |
This page is for informational purposes only and does not replace medical advice. Before using any prescription or over-the-counter medication for Vilazodone, you must consult a qualified healthcare professional.
| 20 mg/1 | TABLET | ORAL | 42291-949 |
| 10 mg/1 | TABLET | ORAL | 60505-4772 |
| 40 mg/1 | TABLET | ORAL | 60505-4774 |
Detailed information about Vilazodone
Vilazodone is a Serotonin Partial Agonist and Reuptake Inhibitor (SPARI) used to treat major depressive disorder. It works by increasing serotonin levels and modulating specific serotonin receptors.
The standard dosing regimen for vilazodone in adults follows a strict titration schedule to minimize gastrointestinal side effects and allow the body to adjust to the medication. According to the FDA-approved labeling, the typical progression is as follows:
In some clinical scenarios, a healthcare provider may decide that 20 mg is the optimal maintenance dose for a specific patient based on their response and tolerability. The maximum recommended dose is 40 mg per day. Doses higher than 40 mg have not shown additional benefit in clinical trials but do increase the risk of adverse events.
Safety and effectiveness in pediatric patients (under the age of 18) have not been established. Vilazodone is not currently FDA-approved for use in children or adolescents. Clinical trials in pediatric populations have not demonstrated sufficient efficacy to warrant approval, and like all antidepressants, vilazodone carries a 'Black Box Warning' regarding the increased risk of suicidal thoughts and behaviors in children, adolescents, and young adults.
For patients with mild to moderate renal (kidney) impairment, no dosage adjustment is typically required. Data on patients with severe renal impairment or end-stage renal disease are limited; therefore, healthcare providers should exercise caution and monitor these patients closely.
No dosage adjustment is necessary for patients with mild to moderate hepatic (liver) impairment (Child-Pugh Class A or B). Vilazodone has not been adequately studied in patients with severe hepatic impairment, and its use in this population is generally not recommended.
Clinical studies did not identify significant differences in safety or efficacy between patients over 65 and younger patients. However, because elderly patients are more likely to have decreased renal or hepatic function and are at higher risk for hyponatremia (low blood sodium), healthcare providers may start at the lower end of the dosing range and monitor closely.
To achieve the best results and minimize side effects, follow these specific instructions:
If you miss a dose of vilazodone, take it as soon as you remember with food. However, if it is almost time for your next scheduled dose, skip the missed dose and resume your regular schedule. Do not take two doses at once to make up for a missed one, as this increases the risk of side effects and toxicity.
An overdose of vilazodone can be dangerous. Symptoms of overdose may include severe drowsiness, vomiting, rapid heartbeat (tachycardia), or serotonin syndrome symptoms (hallucinations, loss of coordination, severe muscle stiffness).
> Important: Follow your healthcare provider's dosing instructions precisely. Do not adjust your dose or stop taking the medication without medical guidance, as sudden discontinuation can lead to withdrawal symptoms.
Vilazodone is most frequently associated with gastrointestinal (GI) side effects, particularly during the first few weeks of treatment as the body adjusts to increased serotonin levels. Because a large portion of the body's serotonin receptors are located in the gut, these effects are common across the SPARI and SSRI classes.
Vilazodone is a potent psychotropic medication that requires careful medical supervision. It is not suitable for everyone, and certain pre-existing conditions can increase the risk of dangerous complications. Before starting treatment, ensure your doctor has a full picture of your medical history, including any history of substance abuse or previous reactions to antidepressants.
Suicidal Thoughts and Behaviors: As mandated by the FDA, vilazodone carries a warning regarding the increased risk of suicidal ideation and behavior in pediatric and young adult patients. While this risk has not been shown to increase in adults over age 24, and actually decreases in those over 65, clinical worsening can occur in any patient. Healthcare providers must weigh the risks of untreated depression against the risks of the medication. Constant vigilance during the first few months of therapy and during dose changes is essential.
There are specific circumstances where vilazodone must never be used because the risks far outweigh any potential benefits.
These are conditions where the doctor must perform a careful risk-benefit analysis before prescribing:
Pregnancy Category: The FDA no longer uses the A-B-C-D-X categories, but the clinical data for vilazodone suggests caution.
Vilazodone is a Serotonin Partial Agonist and Reuptake Inhibitor (SPARI). Its primary therapeutic activity is thought to be related to its enhancement of serotonergic activity in the CNS through selective inhibition of serotonin reuptake. Additionally, it binds with high affinity to 5-HT1A receptors as a partial agonist. It does not have significant affinity for norepinephrine or dopamine transporters. This specific combination of SERT inhibition and 5-HT1A partial agonism is unique to vilazodone and its successor, vortioxetine.
Vilazodone binds to the human serotonin reuptake site with high affinity (Ki = 0.1 nM) and to the 5-HT1A receptor (Ki = 0.3 nM). It has negligible affinity for other serotonin receptors (5-HT2A, 5-HT2C) or for alpha-adrenergic, histamine, or muscarinic receptors. This selectivity helps explain why it lacks the anticholinergic side effects (like blurry vision and constipation) common in older tricyclic antidepressants.
| Parameter | Value |
|---|---|
Common questions about Vilazodone
Vilazodone is an FDA-approved prescription medication used specifically for the treatment of Major Depressive Disorder (MDD) in adults. It belongs to a unique class of drugs known as SPARIs, which work by increasing the levels of serotonin in the brain while also partially stimulating specific serotonin receptors. By balancing these neurotransmitters, it helps improve mood, sleep, and appetite in people suffering from clinical depression. It is not approved for use in children or for other conditions like Bipolar Disorder. Your doctor will determine if your symptoms meet the criteria for MDD before prescribing this medication.
The most frequently reported side effects of vilazodone are gastrointestinal in nature, including diarrhea, nausea, and vomiting. These symptoms often occur during the first week or two of treatment as the body adjusts to the medication. Other common side effects include insomnia (difficulty sleeping), dizziness, and dry mouth. Most of these effects are mild to moderate and tend to diminish over time. However, if these symptoms become severe or persistent, you should contact your healthcare provider. Taking the medication with a full meal can significantly reduce the severity of nausea and diarrhea.
It is strongly recommended that you avoid or strictly limit alcohol consumption while taking vilazodone. Alcohol is a central nervous system depressant that can worsen the symptoms of depression and counteract the benefits of the medication. Additionally, combining alcohol with vilazodone can increase the risk of side effects like extreme drowsiness, dizziness, and impaired coordination. Because both substances are processed by the liver, concurrent use may also increase the risk of liver strain. Always discuss your alcohol intake habits with your doctor before starting any antidepressant therapy.
The safety of vilazodone during pregnancy has not been fully established through large-scale human studies. While animal studies have not shown a high risk of birth defects, taking antidepressants during the third trimester may lead to complications in the newborn, such as breathing difficulties or withdrawal symptoms. The decision to use vilazodone during pregnancy involves a careful risk-benefit analysis by your doctor, weighing the risks to the fetus against the risks of untreated maternal depression. If you become pregnant while taking vilazodone, do not stop the medication abruptly; instead, contact your doctor immediately to discuss a management plan.
Like most antidepressants, vilazodone does not work immediately. While some patients may notice slight improvements in sleep or energy within the first 1 to 2 weeks, the full antidepressant effect typically takes 4 to 8 weeks of consistent use. It is important to continue taking the medication exactly as prescribed, even if you do not feel better right away. The initial weeks are often focused on the titration process (increasing the dose from 10mg to 40mg). If you have been taking the target dose for over 6 weeks without any improvement in your mood, consult your doctor about adjusting your treatment plan.
No, you should never stop taking vilazodone suddenly without consulting your doctor. Abruptly discontinuing the medication can lead to 'discontinuation syndrome,' which includes symptoms like 'brain zaps,' dizziness, nausea, irritability, and extreme fatigue. These symptoms occur because the brain needs time to adjust to the lower levels of serotonin. If you and your doctor decide to stop the medication, your doctor will provide a tapering schedule to slowly lower your dose over several weeks. This gradual reduction helps minimize withdrawal symptoms and ensures a safer transition.
If you miss a dose of vilazodone, you should take it as soon as you remember, provided you take it with food. However, if it is almost time for your next scheduled dose, you should skip the missed dose and simply take your next dose at the regular time. Never take two doses at once to 'catch up,' as this can significantly increase your risk of side effects like nausea or serotonin syndrome. Consistency is key to the effectiveness of vilazodone, so try to incorporate it into a daily routine, such as taking it every day with breakfast.
In clinical trials, vilazodone was generally found to be 'weight neutral,' meaning patients did not experience significant weight gain or loss compared to those taking a placebo. This is often considered an advantage over older antidepressants, such as tricyclics or certain SSRIs, which are more commonly associated with weight changes. However, every individual reacts differently to medication, and some people may still experience changes in appetite. If you are concerned about your weight while taking vilazodone, discuss a nutrition and exercise plan with your healthcare provider to monitor and manage your health effectively.
Vilazodone can interact with many other medications, some of which can cause serious safety issues. It should never be taken with MAOIs, and caution is required when combining it with other serotonergic drugs (like triptans or lithium) or blood thinners (like aspirin or warfarin). Some medications, such as certain antibiotics or antifungals, can change the levels of vilazodone in your blood, requiring a dose adjustment. Always provide your doctor and pharmacist with a complete list of all prescription drugs, over-the-counter medicines, and herbal supplements you are taking to avoid dangerous interactions.
Yes, vilazodone is currently available as a generic medication. The generic version, vilazodone hydrochloride, contains the same active ingredient and meets the same FDA standards for safety and effectiveness as the brand-name version, Viibryd. Generic medications are typically more affordable and are covered by most insurance plans. When you receive your prescription, it may be labeled as either Viibryd or Vilazodone HCl. If you have questions about the cost or the specific manufacturer of your generic medication, your pharmacist can provide detailed information.
Other drugs with the same active ingredient (Vilazodone)
While rare, some side effects are medical emergencies.
> Warning: Stop taking Vilazodone and call your doctor immediately if you experience any of these.
Prolonged use of vilazodone is generally well-tolerated. However, long-term considerations include:
Suicidality and Antidepressant Drugs: The FDA requires a 'Black Box Warning'—its most serious warning—on all antidepressants, including vilazodone.
Report any unusual symptoms to your healthcare provider. Do not attempt to treat serious side effects at home.
While vilazodone does not require frequent therapeutic drug monitoring (blood draws for drug levels), your doctor will likely perform the following:
Vilazodone may cause dizziness, fatigue, or blurred vision, particularly during the first few weeks of treatment or after a dose increase. You should not drive, operate heavy machinery, or engage in potentially dangerous activities until you know how vilazodone affects you. If you feel sedated or 'foggy,' consult your doctor.
Combining vilazodone with alcohol is strongly discouraged. Alcohol can worsen the side effects of vilazodone, such as dizziness and drowsiness, and can also counteract the antidepressant effects of the medication, making your depression harder to treat. Furthermore, both substances are processed by the liver, and combining them can increase the metabolic burden.
Discontinuation Syndrome: You must never stop taking vilazodone abruptly. Doing so can cause 'withdrawal-like' symptoms, including:
When it is time to stop the medication, your healthcare provider will provide a tapering schedule to gradually reduce the dose over several weeks.
> Important: Discuss all your medical conditions, including any history of glaucoma, bleeding disorders, or liver/kidney disease, with your healthcare provider before starting Vilazodone.
There are no known common laboratory test interactions where vilazodone causes false positives on standard drug screens. However, always inform the laboratory staff that you are taking this medication if you are undergoing specialized testing.
For each major interaction, the primary management strategy is medical supervision. Do not start or stop any other medication while on vilazodone without consulting your pharmacist or doctor.
> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking, including over-the-counter pain relievers and allergy medications.
While vilazodone is chemically distinct from other SSRIs, patients who have experienced severe 'Serotonin Syndrome' or 'Neuroleptic Malignant Syndrome' in response to other psychotropic drugs should be monitored with extreme care, as they may have a biological predisposition to adverse serotonin reactions.
> Important: Your healthcare provider will evaluate your complete medical history, including any history of 'suicide attempts' or 'alcoholism,' before prescribing Vilazodone.
Vilazodone is not approved for use in patients under 18 years of age. In clinical trials, the drug did not show a statistically significant benefit over placebo in children and adolescents with MDD. Furthermore, the risk of suicidal ideation is a primary concern in this age group.
In general, dose selection for an elderly patient should be cautious.
> Important: Special populations require individualized medical assessment. Always inform your obstetrician or pediatrician if you are taking Vilazodone.
| Protein Binding | 96% - 99% |
| Half-life | ~25 hours |
| Tmax | 4 - 5 hours |
| Metabolism | CYP3A4 (Major), CYP2C19, CYP2D6 |
| Excretion | Fecal 64%, Renal 26% |
Vilazodone is classified as a SPARI (Serotonin Partial Agonist and Reuptake Inhibitor). It is therapeutically grouped with other 'atypical' or 'multimodal' antidepressants. While it shares the reuptake inhibition of SSRIs (like Prozac or Zoloft), its partial agonism at 5-HT1A distinguishes it from the standard SSRI class.